Scientific Reports (Jan 2023)

A novel NONO variant that causes developmental delay and cardiac phenotypes

  • Toshiyuki Itai,
  • Atsushi Sugie,
  • Yohei Nitta,
  • Ryuto Maki,
  • Takashi Suzuki,
  • Yoichi Shinkai,
  • Yoshihiro Watanabe,
  • Yusuke Nakano,
  • Kazushi Ichikawa,
  • Nobuhiko Okamoto,
  • Yasuhiro Utsuno,
  • Eriko Koshimizu,
  • Atsushi Fujita,
  • Kohei Hamanaka,
  • Yuri Uchiyama,
  • Naomi Tsuchida,
  • Noriko Miyake,
  • Kazuharu Misawa,
  • Takeshi Mizuguchi,
  • Satoko Miyatake,
  • Naomichi Matsumoto

DOI
https://doi.org/10.1038/s41598-023-27770-6
Journal volume & issue
Vol. 13, no. 1
pp. 1 – 9

Abstract

Read online

Abstract The Drosophila behavior/human splicing protein family is involved in numerous steps of gene regulation. In humans, this family consists of three proteins: SFPQ, PSPC1, and NONO. Hemizygous loss-of-function (LoF) variants in NONO cause a developmental delay with several complications (e.g., distinctive facial features, cardiac symptoms, and skeletal symptoms) in an X-linked recessive manner. Most of the reported variants have been LoF variants, and two missense variants have been reported as likely deleterious but with no functional validation. We report three individuals from two families harboring an identical missense variant that is located in the nuclear localization signal, NONO: NM_001145408.2:c.1375C > G p.(Pro459Ala). All of them were male and the variant was inherited from their asymptomatic mothers. Individual 1 was diagnosed with developmental delay and cardiac phenotypes (ventricular tachycardia and dilated cardiomyopathy), which overlapped with the features of reported individuals having NONO LoF variants. Individuals 2 and 3 were monozygotic twins. Unlike in Individual 1, developmental delay with autistic features was the only symptom found in them. A fly experiment and cell localization experiment showed that the NONO variant impaired its proper intranuclear localization, leading to mild LoF. Our findings suggest that deleterious NONO missense variants should be taken into consideration when whole-exome sequencing is performed on male individuals with developmental delay with or without cardiac symptoms.